Parathyroid Hormone: Anabolic Treatment of Osteoporosis

Osteoporosis ◽  
2013 ◽  
pp. 158-177
Author(s):  
Erik Fink Eriksen
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Anabolic Treatment

Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats

2017 ◽  
Vol 7 (4) ◽  
pp. 482-496 ◽  
Author(s):  
Yang Yang ◽  
Ali Aghazadeh-Habashi ◽  
Arash Panahifar ◽  
Yuchin Wu ◽  
Krishna H. Bhandari ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Bone Targeting ◽  
Anabolic Treatment

scholarly journals The use of PTH in the treatment of osteoporosis

2010 ◽  
Vol 54 (2) ◽  
pp. 213-219 ◽  
Author(s):  
Victória Z. Cochenski Borba ◽  
Nádila Cecyn Pietszkowski Mañas
Keyword(s):  
Parathyroid Hormone ◽  
Bone Density ◽  
Adverse Effects ◽  
Combination Therapy ◽  
Biochemical Markers ◽  
Osteoporosis Treatment ◽  
Antiresorptive Therapy ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents ◽  
Anabolic Treatment

Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis.

scholarly journals Malignant Myeloma in a Patient after Treatment for Osteoporosis with Teriparatide; a Rare Coincidence

2008 ◽  
Vol 1 ◽  
pp. CCRep.S1026 ◽  
Author(s):  
Terje Forslund ◽  
Anna-Mari Koski ◽  
Arvo Koistinen ◽  
Anu Sikiö
Keyword(s):  
Parathyroid Hormone ◽  
Theoretical Basis ◽  
Bone Structure ◽  
Exclusion Criterion ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Teriparatide Treatment ◽  
Direct Association ◽  
Metastasis Development ◽  
Structure Regulation

A breakthrough in understanding of mechanisms of bone structure regulation has brought about the introduction of the new synthetic recombinant human parathyroid hormone 1–34 (PTH1-34; Teriparatide) in the treatment of osteoporosis. These mechanisms, involving the RANKL, RANK, and osteoprotegerin system, are also known to be involved in malignant myeloma (MM) and tumor and bone metastasis development. We report a case in which MM was found after treatment of osteoporosis with teriparatide. We were unable to demonstrate any direct association between the MM and teriparatide treatment. However, it seemed intriguing that similar mechanisms are activated in the development of MM as those being working during teriparatide treatment. In the view of our case, we propose that MM by examination of serum protein fraction should be searched for prior to treatment with teriparatide as it is an exclusion criterion in teriparatide treatment of secondary osteoporosis. A search for other metastatic diseases prior to teriparatide treatment should eventually also be considered. The theoretical basis for our proposal is discussed.

A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis

Peptides ◽  
2009 ◽  
Vol 30 (6) ◽  
pp. 1173-1180 ◽  
Author(s):  
Jiao Feng ◽  
Yanhua Liu ◽  
Yun Xing ◽  
Huaqian Wang ◽  
Taiming Li ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis

Parathyroid hormone analogues for treatment of osteoporosis and hypercalcaemia

1998 ◽  
Vol 8 (1) ◽  
pp. 31-37 ◽  
Author(s):  
Paul Morley ◽  
James F Whitfield ◽  
Gordon Willick
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis

scholarly journals Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use

2005 ◽  
Vol 26 (5) ◽  
pp. 688-703 ◽  
Author(s):  
Anthony B. Hodsman ◽  
Douglas C. Bauer ◽  
David W. Dempster ◽  
Larry Dian ◽  
David A. Hanley ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis

Preliminary Trial of Low Doses of Human Parathyroid Hormone 1–34 Peptide in Treatment of Osteoporosis

1976 ◽  
Vol 50 (2) ◽  
pp. 14P-14P
Author(s):  
J. Reeve ◽  
J. A. Parsons ◽  
G. W. Tregear ◽  
A. J. Darby ◽  
R. Hesp ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Low Doses ◽  
Human Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Preliminary Trial

scholarly journals In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1–34 for the treatment of osteoporosis

2018 ◽  
Vol 535 (1-2) ◽  
pp. 113-119 ◽  
Author(s):  
Allan J. Williams ◽  
Faron Jordan ◽  
Gareth King ◽  
Andrew L. Lewis ◽  
Lisbeth Illum ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis ◽  
Spray Formulation ◽  
Intranasal Spray

Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide

2009 ◽  
Vol 84 (3) ◽  
pp. 159-170 ◽  
Author(s):  
Johannes Pleiner-Duxneuner ◽  
Elisabeth Zwettler ◽  
Eleftherios Paschalis ◽  
Paul Roschger ◽  
Valerie Nell-Duxneuner ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Treatment Of Osteoporosis
Sign in / Sign up

Export Citation Format

Share Document